Evidence map›Paper›PMID 31893584›Full record

ArticleBalkan medical journal2020

R-(-)-carvone Attenuated Doxorubicin Induced Cardiotoxicity

Manal Mohammad Abbas, Yasser İbrahim Kandil, Manal Ahmad Abbas

Open access · diamondAbstract read
In one paragraph

Article in Balkan medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The flavonoid ofFrontiers in pharmacology · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Molecules (Basel, Switzerland) · 2022
    Review
  14. Article
  15. Advocacy for the Medicinal PlantMolecules (Basel, Switzerland) · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. International journal of breast cancer · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Manal Mohammad AbbasSchool of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, JordanORCID 0000-0002-8962-1879
Yasser İbrahim KandilSchool of Pharmacy, Al-Ahliyya Amman University, Amman, JordanORCID 0000-0002-7156-9208
Manal Ahmad AbbasSchool of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, JordanORCID 0000-0002-7991-3827
Al-Ahliyya Amman University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Doxorubicin is one of the most potent broad-spectrum antitumor and chemotherapeutic agents. However, it produces cardiotoxicity. Aims: To investigate whether R-(-)-carvone exerts a cardioprotective effect against doxorubicin toxicity Study Design: Cell culture and animal experiment. Methods: The synergistic effect of R-(-)-carvone with doxorubicin was evaluated in the MCF 7 cancer cell line while its protective effect against doxorubicin toxicity was evaluated in the normal heart cell line (H9C2) and Results: R-(-)-carvone exerted cytotoxic action on the MCF 7 cancer cell line with an IC Conclusion: R-(-)-carvone has synergistic anticancer action with doxorubicin on the MCF 7 cell line while decreasing its cardiotoxicity.

Indexed as

AnimalsAntineoplastic AgentsAntineoplastic Agents, PhytogenicCardiotoxicityCyclohexane MonoterpenesDisease Models, AnimalDoxorubicinHeartMiceMice, Inbred BALB CProtective FactorsAntineoplastic AgentsAntineoplastic Agents, PhytogeniccarvoneCyclohexane MonoterpenesDoxorubicinCardiotoxicitycatalasedoxorubicinH9C2MCF 7R-(-)-carvone

Identifiers

PMID31893584
PMCPMC7094179
OpenAlexW2998520742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.